Market research
ALEC Alector Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 264M
- P/E ratio
- Not available
- Analyst target
- 3.1
- Dividend yield
- Not available
- Beta
- 0.58
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0144421072
- Market cap
- 264M
- P/E ratio
- Not available
- Analyst target
- 3.1
- Dividend yield
- Not available
- Beta
- 0.58
About
About Alector Inc
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ALEC discussion.
5 years, 4 months ago
Alector, Inc is currently in a long term uptrend where the price is trading 130.4% above its 200 day moving average.
From a valuation standpoint, the stock is 94.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 73.7.
Alector, Inc's total revenue sank by 19.1% to $5M since the same quarter in the previous year.
Its net income has dropped by 70.9% to $-52M since the same quarter in the previous year.
Finally, its free cash flow fell by 59.4% to $-48M since the same quarter in the previous year.
Based on the above factors, Alector, Inc gets an overall score of 2/5.